Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 234

1.

Contribution of Fcγ receptor IIB to creating a suppressive tumor microenvironment in a mouse model.

Kasahara Y, Shirota H, Umegaki S, Ishioka C.

Cancer Immunol Immunother. 2019 Oct 15. doi: 10.1007/s00262-019-02413-w. [Epub ahead of print]

PMID:
31616964
2.

Importance of gastric cancer for the diagnosis and surveillance of Japanese Lynch syndrome patients.

Ikenoue T, Arai M, Ishioka C, Iwama T, Kaneko S, Matsubara N, Moriya Y, Nomizu T, Sugano K, Tamura K, Tomita N, Yoshida T, Sugihara K, Naruse H, Yamaguchi K, Nojima M, Nakamura Y, Furukawa Y; Japanese society for cancer of the colon and rectum (JSCCR).

J Hum Genet. 2019 Oct 7. doi: 10.1038/s10038-019-0674-5. [Epub ahead of print]

PMID:
31588121
3.

In Vitro and in Vivo antitumor activity and the mechanism of siphonodictyal B in human colon cancer cells.

Chikamatsu S, Saijo K, Imai H, Narita K, Kawamura Y, Katoh T, Ishioka C.

Cancer Med. 2019 Sep;8(12):5662-5672. doi: 10.1002/cam4.2409. Epub 2019 Jul 31.

4.

Therapeutic Benefits of Ipilimumab among Japanese Patients with Nivolumab-Refractory Mucosal Melanoma: A Case Series Study.

Saijo K, Imai H, Ouchi K, Okada Y, Sato Y, Komine K, Takahashi M, Takahashi S, Shirota H, Takahashi M, Ishioka C.

Tohoku J Exp Med. 2019 May;248(1):37-43. doi: 10.1620/tjem.248.37.

5.

A comparative analysis of clinicopathological factors between esophageal small cell and basaloid squamous cell carcinoma.

Ishida H, Kasajima A, Onodera Y, Konno T, Maruyama S, Okamoto H, Sato C, Heishi T, Sakurai T, Taniyama Y, Takahashi M, Fujishima F, Jingu K, Ishioka C, Sasano H, Kamei T.

Medicine (Baltimore). 2019 Feb;98(8):e14363. doi: 10.1097/MD.0000000000014363.

6.

RACK1 regulates centriole duplication by controlling localization of BRCA1 to the centrosome in mammary tissue-derived cells.

Yoshino Y, Qi H, Kanazawa R, Sugamata M, Suzuki K, Kobayashi A, Shindo K, Matsuzawa A, Shibata S, Endo S, Miyanishi Y, Shimaoka T, Ishioka C, Kanno SI, Yasui A, Chiba N.

Oncogene. 2019 Apr;38(16):3077-3092. doi: 10.1038/s41388-018-0647-8. Epub 2019 Jan 7.

PMID:
30617304
7.

Predictive factors for the efficacy of the second taxane treatment in patients with advanced cancer.

Imai H, Saijo K, Komine K, Kawamura Y, Hiraide S, Umegaki S, Okada Y, Ohuchi K, Sato Y, Takahashi M, Takahashi S, Shirota H, Takahashi M, Ishioka C.

Cancer Manag Res. 2018 Sep 17;10:3629-3636. doi: 10.2147/CMAR.S170948. eCollection 2018.

8.

Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0).

Sunami K, Takahashi H, Tsuchihara K, Takeda M, Suzuki T, Naito Y, Sakai K, Dosaka-Akita H, Ishioka C, Kodera Y, Muto M, Wakai T, Yamazaki K, Yasui W, Bando H, Fujimoto Y, Fukuoka S, Harano K, Kawazoe A, Kimura G, Koganemaru S, Kogawa T, Kotani D, Kuboki Y, Matsumoto H, Matsumoto S, Mishima S, Nakamura Y, Sawada K, Shingaki S, Shitara K, Umemoto K, Umemura S, Yasuda K, Yoshino T, Yamamoto N, Nishio K; Japanese Society of Medical Oncology; Japan Society of Clinical Oncology; Japanese Cancer Association.

Cancer Sci. 2018 Sep;109(9):2980-2985. doi: 10.1111/cas.13730.

9.

End-of-life care for cancer patients in Japanese acute care hospitals: A nationwide retrospective administrative database survey.

Sato Y, Miyashita M, Sato K, Fujimori K, Ishikawa KB, Horiguchi H, Fushimi K, Ishioka C.

Jpn J Clin Oncol. 2018 Oct 1;48(10):877-883. doi: 10.1093/jjco/hyy117.

PMID:
30107588
10.

Patient perceptions of curability and physician-reported disclosures of incurability in Japanese patients with unresectable/recurrent cancer: a cross-sectional survey.

Oishi T, Sato K, Morita T, Mack JW, Shimodaira H, Takahashi M, Takahashi S, Inoue A, Murakawa Y, Kawahara M, Ishioka C, Miyashita M.

Jpn J Clin Oncol. 2018 Oct 1;48(10):913-919. doi: 10.1093/jjco/hyy112.

PMID:
30102399
11.

Efficacy and Safety of Trastuzumab in Combination with S-1 and Cisplatin Therapy for Japanese Patients with HER2-Positive Advanced Gastric Cancer: Retrospective Analysis.

Okita A, Imai H, Takahashi M, Takahashi H, Umegaki S, Kawamura Y, Hiraide S, Ouchi K, Sato Y, Okada Y, Komine K, Saijo K, Takahashi S, Takahashi M, Shirota H, Ohori H, Gamoh M, Ishioka C.

Tohoku J Exp Med. 2018 Jun;245(2):123-129. doi: 10.1620/tjem.245.123.

12.

BRCA1-Interacting Protein OLA1 Requires Interaction with BARD1 to Regulate Centrosome Number.

Yoshino Y, Qi H, Fujita H, Shirota M, Abe S, Komiyama Y, Shindo K, Nakayama M, Matsuzawa A, Kobayashi A, Ogoh H, Watanabe T, Ishioka C, Chiba N.

Mol Cancer Res. 2018 Oct;16(10):1499-1511. doi: 10.1158/1541-7786.MCR-18-0269. Epub 2018 Jun 1.

13.

Intermittent Withdrawal of Oxaliplatin for Alleviating Neurotoxicity during Oxaliplatin-Based Chemotherapy for Japanese Patients with Inoperable or Metastatic Colorectal Cancer: A Phase 2 Multicenter Study.

Kato S, Imai H, Gamoh M, Takahata T, Ohori H, Yasuda K, Niitani T, Murakawa Y, Amagai K, Isobe H, Shindo Y, Kuroki M, Sakamoto Y, Shimodaira H, Yoshioka T, Ishioka C.

Tohoku J Exp Med. 2018 May;245(1):21-28. doi: 10.1620/tjem.245.21.

14.

Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer.

Okita A, Takahashi S, Ouchi K, Inoue M, Watanabe M, Endo M, Honda H, Yamada Y, Ishioka C.

Oncotarget. 2018 Apr 10;9(27):18698-18711. doi: 10.18632/oncotarget.24617. eCollection 2018 Apr 10.

15.

Molecular and clinical features of the TP53 signature gene expression profile in early-stage breast cancer.

Yamaguchi S, Takahashi S, Mogushi K, Izumi Y, Nozaki Y, Nomizu T, Kakugawa Y, Ishida T, Ohuchi N, Ishioka C, Kato S.

Oncotarget. 2018 Feb 8;9(18):14193-14206. doi: 10.18632/oncotarget.24447. eCollection 2018 Mar 6.

16.

Alcohol consumption and early-onset risk of colorectal cancer in Japanese patients with Lynch syndrome: a cross-sectional study conducted by the Japanese Society for Cancer of the Colon and Rectum.

Miguchi M, Hinoi T, Tanakaya K, Yamaguchi T, Furukawa Y, Yoshida T, Tamura K, Sugano K, Ishioka C, Matsubara N, Tomita N, Arai M, Ishikawa H, Hirata K, Saida Y, Ishida H, Sugihara K.

Surg Today. 2018 Aug;48(8):810-814. doi: 10.1007/s00595-018-1654-7. Epub 2018 Mar 24.

PMID:
29574523
17.

Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors.

Ouchi K, Takahashi S, Chikamatsu S, Ito S, Takahashi Y, Kawai S, Okita A, Kasahara Y, Okada Y, Imai H, Komine K, Saijo K, Takahashi M, Shirota H, Takahashi M, Gamoh M, Ishioka C.

Int J Clin Oncol. 2018 Aug;23(4):790-798. doi: 10.1007/s10147-018-1261-z. Epub 2018 Mar 7.

18.

[Why Cardio-Oncology Is Necessary Today - From a Viewpoint of the Tumor Internal Medicine].

Ishioka C.

Gan To Kagaku Ryoho. 2017 Dec;44(13):2048-2051. Japanese.

PMID:
29361615
19.

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.

Yamada Y, Denda T, Gamoh M, Iwanaga I, Yuki S, Shimodaira H, Nakamura M, Yamaguchi T, Ohori H, Kobayashi K, Tsuda M, Kobayashi Y, Miyamoto Y, Kotake M, Shimada K, Sato A, Morita S, Takahashi S, Komatsu Y, Ishioka C.

Ann Oncol. 2018 Mar 1;29(3):624-631. doi: 10.1093/annonc/mdx816.

20.

microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer.

Takahashi H, Takahashi M, Ohnuma S, Unno M, Yoshino Y, Ouchi K, Takahashi S, Yamada Y, Shimodaira H, Ishioka C.

BMC Cancer. 2017 Nov 7;17(1):723. doi: 10.1186/s12885-017-3739-x.

21.

Guidelines for treatment of renal injury during cancer chemotherapy 2016.

Horie S, Oya M, Nangaku M, Yasuda Y, Komatsu Y, Yanagita M, Kitagawa Y, Kuwano H, Nishiyama H, Ishioka C, Takaishi H, Shimodaira H, Mogi A, Ando Y, Matsumoto K, Kadowaki D, Muto S.

Clin Exp Nephrol. 2018 Feb;22(1):210-244. doi: 10.1007/s10157-017-1448-z. Review. No abstract available.

22.

IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model.

Ito SE, Shirota H, Kasahara Y, Saijo K, Ishioka C.

Cancer Immunol Immunother. 2017 Nov;66(11):1485-1496. doi: 10.1007/s00262-017-2043-6. Epub 2017 Jul 21.

PMID:
28733709
23.

The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: A retrospective, single institutional study.

Takahashi M, Takahashi M, Komine K, Yamada H, Kasahara Y, Chikamatsu S, Okita A, Ito S, Ouchi K, Okada Y, Imai H, Saijo K, Shirota H, Takahashi S, Mori T, Shimodaira H, Ishioka C.

PLoS One. 2017 Jun 22;12(6):e0179694. doi: 10.1371/journal.pone.0179694. eCollection 2017.

24.

Synthetic lethal interaction of CDK inhibition and autophagy inhibition in human solid cancer cell lines.

Okada Y, Kato S, Sakamoto Y, Oishi T, Ishioka C.

Oncol Rep. 2017 Jul;38(1):31-42. doi: 10.3892/or.2017.5684. Epub 2017 May 30.

25.

Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis.

Takahashi M, Komine K, Imai H, Okada Y, Saijo K, Takahashi M, Shirota H, Ohori H, Takahashi S, Chiba N, Mori T, Shimodaira H, Ishioka C.

PLoS One. 2017 May 10;12(5):e0176972. doi: 10.1371/journal.pone.0176972. eCollection 2017.

26.

Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/ phosphatidylinositol 3-kinase dual inhibitor.

Saijo K, Imai H, Chikamatsu S, Narita K, Katoh T, Ishioka C.

Cancer Sci. 2017 Jul;108(7):1469-1475. doi: 10.1111/cas.13255. Epub 2017 May 19.

27.

[Resection of a Huge Gastrointestinal Stromal Tumor of the Stomach Following Neoadjuvant Chemotherapy with Imatinib].

Sato Y, Karasawa H, Aoki T, Imoto H, Tanaka N, Watanabe K, Abe T, Nagao M, Ohnuma S, Musha H, Takahashi M, Motoi F, Naitoh T, Ishioka C, Unno M.

Gan To Kagaku Ryoho. 2016 Nov;43(12):2216-2218. Japanese.

PMID:
28133274
28.

IL4 from T Follicular Helper Cells Downregulates Antitumor Immunity.

Shirota H, Klinman DM, Ito SE, Ito H, Kubo M, Ishioka C.

Cancer Immunol Res. 2017 Jan;5(1):61-71. doi: 10.1158/2326-6066.CIR-16-0113. Epub 2016 Dec 5.

29.

Reversibility of the thia-Michael reaction of cytotoxic C5-curcuminoid and structure-activity relationship of bis-thiol-adducts thereof.

Kohyama A, Fukuda M, Sugiyama S, Yamakoshi H, Kanoh N, Ishioka C, Shibata H, Iwabuchi Y.

Org Biomol Chem. 2016 Dec 7;14(45):10683-10687. Epub 2016 Nov 1.

PMID:
27801454
30.

In vitro chromosomal aberrations induced by various shapes of multi-walled carbon nanotubes (MWCNTs).

Sasaki T, Asakura M, Ishioka C, Kasai T, Katagiri T, Fukushima S.

J Occup Health. 2016 Nov 29;58(6):622-631. Epub 2016 Oct 7.

31.

CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.

Zhang X, Shimodaira H, Soeda H, Komine K, Takahashi H, Ouchi K, Inoue M, Takahashi M, Takahashi S, Ishioka C.

Int J Clin Oncol. 2016 Dec;21(6):1091-1101. Epub 2016 Jul 19.

PMID:
27435270
32.

Current situation regarding central venous port implantation procedures and complications: a questionnaire-based survey of 11,693 implantations in Japan.

Shiono M, Takahashi S, Takahashi M, Yamaguchi T, Ishioka C.

Int J Clin Oncol. 2016 Dec;21(6):1172-1182. Epub 2016 Jun 21.

PMID:
27324107
33.

OLA1 gene sequencing in patients with BRCA1/2 mutation-negative suspected hereditary breast and ovarian cancer.

Takahashi M, Chiba N, Shimodaira H, Yoshino Y, Mori T, Sumii M, Nomizu T, Ishioka C.

Breast Cancer. 2017 Mar;24(2):336-340. doi: 10.1007/s12282-016-0709-0. Epub 2016 Jun 6.

PMID:
27271530
34.

Successful sequential treatment of a patient with advanced gastrointestinal stromal tumor using four different molecularly targeted drugs.

Sugiyama S, Ishizuka M, Takahashi M, Komine K, Imai H, Saijo K, Takahashi M, Shirota H, Takahashi S, Shimodaira H, Ishioka C.

Int Cancer Conf J. 2016 Apr 28;5(4):163-167. doi: 10.1007/s13691-016-0250-1. eCollection 2016 Oct.

35.

Causes of Cancer Death Among First-Degree Relatives in Japanese Families with Lynch Syndrome.

Tanakaya K, Yamaguchi T, Ishikawa H, Hinoi T, Furukawa Y, Hirata K, Saida Y, Shimokawa M, Arai M, Matsubara N, Tomita N, Tamura K, Sugano K, Ishioka C, Yoshida T, Ishida H, Watanabe T, Sugihara K; for HNPCC Registry and Genetic Testing Project of the Japanese Society for Cancer of the Colon and Rectum.

Anticancer Res. 2016 Apr;36(4):1985-9.

PMID:
27069191
36.

Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma.

Imai H, Komine K, Takahashi S, Saijo K, Okada Y, Kobayashi A, Okita A, Chikamatsu S, Kasahara Y, Takahashi M, Oishi T, Shirota H, Takahashi M, Shimodaira H, Ishioka C.

Chemotherapy. 2016;61(5):262-8. doi: 10.1159/000444122. Epub 2016 Apr 5.

PMID:
27043795
37.

Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease.

Kobayashi A, Takahashi M, Imai H, Akiyama S, Sugiyama S, Komine K, Saijo K, Takahashi M, Takahashi S, Shirota H, Sato N, Fujishima F, Shuin T, Shimodaira H, Ishioka C.

Intern Med. 2016;55(6):629-34. doi: 10.2169/internalmedicine.55.5796. Epub 2016 Mar 15.

38.

Efficacy and Safety of Carboplatin and Etoposide Combination Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma: A Retrospective Case Series.

Imai H, Shirota H, Okita A, Komine K, Saijo K, Takahashi M, Takahashi S, Takahashi M, Shimodaira H, Ishioka C.

Chemotherapy. 2016;61(3):111-6. doi: 10.1159/000441551. Epub 2015 Dec 5.

PMID:
26636658
39.

A Curcumin Analog, GO-Y078, Effectively Inhibits Angiogenesis through Actin Disorganization.

Sugiyama S, Yoshino Y, Kuriyama S, Inoue M, Komine K, Otsuka K, Kohyama A, Yamakoshi H, Ishioka C, Tanaka M, Iwabuchi Y, Shibata H.

Anticancer Agents Med Chem. 2016;16(5):633-47.

PMID:
26459768
40.

DNA methylation status as a biomarker of anti-epidermal growth factor receptor treatment for metastatic colorectal cancer.

Ouchi K, Takahashi S, Yamada Y, Tsuji S, Tatsuno K, Takahashi H, Takahashi N, Takahashi M, Shimodaira H, Aburatani H, Ishioka C.

Cancer Sci. 2015 Dec;106(12):1722-9. doi: 10.1111/cas.12827. Epub 2015 Nov 12.

41.

Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer.

Komatsu Y, Ishioka C, Shimada K, Yamada Y, Gamoh M, Sato A, Yamaguchi T, Yuki S, Morita S, Takahashi S, Goto R, Kurihara M.

BMC Cancer. 2015 Sep 9;15:626. doi: 10.1186/s12885-015-1630-1.

43.

[Development of biomarkers for molecular target drugs].

Saijo K, Ishioka C.

Nihon Rinsho. 2015 Aug;73(8):1308-12. Review. Japanese.

PMID:
26281683
44.

Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.

Watanabe G, Ishida T, Furuta A, Takahashi S, Watanabe M, Nakata H, Kato S, Ishioka C, Ohuchi N.

Am J Surg Pathol. 2015 Aug;39(8):1026-34. doi: 10.1097/PAS.0000000000000386.

PMID:
26171916
45.

Inhibition of invasion by glycogen synthase kinase-3 beta inhibitors through dysregulation of actin re-organisation via down-regulation of WAVE2.

Yoshino Y, Suzuki M, Takahashi H, Ishioka C.

Biochem Biophys Res Commun. 2015 Aug 14;464(1):275-80. doi: 10.1016/j.bbrc.2015.06.142. Epub 2015 Jun 24.

PMID:
26116771
46.

Somatic alteration and depleted nuclear expression of BAP1 in human esophageal squamous cell carcinoma.

Mori T, Sumii M, Fujishima F, Ueno K, Emi M, Nagasaki M, Ishioka C, Chiba N.

Cancer Sci. 2015 Sep;106(9):1118-29. doi: 10.1111/cas.12722. Epub 2015 Aug 10.

47.

Gene-expression profiles correlate with the efficacy of anti-EGFR therapy and chemotherapy for colorectal cancer.

Inoue M, Takahashi S, Soeda H, Shimodaira H, Watanabe M, Miura K, Sasaki I, Kato S, Ishioka C.

Int J Clin Oncol. 2015 Dec;20(6):1147-55. doi: 10.1007/s10147-015-0841-4. Epub 2015 May 20.

PMID:
25990448
48.

[Present status and future prospect of the chemotherapy for ampullary cancer].

Imai H, Ishioka C.

Nihon Rinsho. 2015 Mar;73 Suppl 3:737-40. Japanese. No abstract available.

PMID:
25857125
49.

[Comprehensive geriatric assessment for elderly patients with cancer].

Takahashi M, Ishioka C.

Nihon Rinsho. 2015 Feb;73 Suppl 2:701-5. Japanese. No abstract available.

PMID:
25831851
50.

[Points of management for elderly patients in chemotherapy].

Komine K, Ishioka C.

Nihon Rinsho. 2015 Feb;73 Suppl 2:51-6. Japanese. No abstract available.

PMID:
25831723

Supplemental Content

Loading ...
Support Center